DHR vs BMY
Danaher · Bristol-Myers Squibb
| DHR Danaher Healthcare | BMY Bristol-Myers Squibb Healthcare | |
|---|---|---|
| Market | ||
| Price | $232.23 -2.00% | $62.48 +1.78% |
| Market cap | $163.4B | $127.6B |
| P/E (TTM) | 37.7 | 13.8 |
| Dividend yield | 0.49% | 4.58% |
| 52-week range | $160.93 – $242.80 | $43.20 – $68.64 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Danaher (DHR): Core Sales Up 3% And Adjusted EPS Up 11.5%, But A Tax Swing Was 81% Of The… Nov 1, 2026 | Bristol-Myers Squibb: The Forensic Case That The Patent Cliff Math Has Already Been Solved May 27, 2026 |
| Latest earnings | ||
| Reported | Oct 21, 2026 | Oct 29, 2026 |
| Revenue | $6.6 billion +8.5% YoY | $13.1 billion +7% YoY |
| EPS | — | $1.05 |
| Guidance | Guidance revised | Guidance raised |
| Revenue growth, last 4 reports | +8.5% | +7% |
| Topics | ||
| Main topics | ||
| Company page · Earnings releases | Company page · Earnings releases | |
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.